# A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

> **NCT04541433** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- ER+ HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** AZD9833

## Key facts

- **NCT ID:** NCT04541433
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-29
- **Primary completion:** 2022-07-29
- **Final completion:** 2025-06-23
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541433, "A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04541433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*